Question 1

What specific benefits might I expect from participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) clinical trial (NCT01362361). Contact the study team or your healthcare provider for specific answers.

Question 2

How does BIBF 1120 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) clinical trial (NCT01362361). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of BIBF 1120?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) clinical trial (NCT01362361). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) clinical trial (NCT01362361). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) clinical trial (NCT01362361). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my insurance cover the costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) clinical trial (NCT01362361). Contact the study team or your healthcare provider for specific answers.

What this study is about